Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.

Antimicrobial agents and chemotherapy - 1 Oct 2011

Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher Kirsty, Morrissey Ian, Soulama-Mouze C

Abstract excerpt

MUT056399 is a highly potent new inhibitor of the FabI enzyme of both Staphylococcus aureus and Escherichia coli. In vitro, MUT056399 was very active against S. aureus strains, including methicillin-susceptible S. aureus (MSSA), methicillin-resistant S. aureus (MRSA), linezolid-resistant, and multidrug-resistant strains, with MIC(90)s between 0.03 and 0.12 μg/ml. MUT056399 was also active against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Linezolid

Share to Methicillin-Resistant Staphylococcus aureus

Share to Oxazolidinones

Share to Staphylococcal Infections

Share to Staphylococcus aureus

Share to Vancomycin

Source

Open in PubMed Open full text

Identifiers

PMID: 21825292
DOI: 10.1128/AAC.01248-10
PMCID: PMC3186954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.PMID 21825292Read ↗

In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in KoreaSemantic proximity Read ↗

An improved small-molecule inhibitor of FtsZ with superior in vitro potency, drug-like properties, and in vivo efficacy.Semantic proximity Read ↗

Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.Semantic proximity Read ↗

An inhibitor of FtsZ with potent and selective anti-staphylococcal activity.Semantic proximity Read ↗

Anti-staphylococcal activity of indolmycin, a potential topical agent for control of staphylococcal infectionsSemantic proximity Read ↗

Genetic Basis of Resistance to Fusidic Acid in StaphylococciSemantic proximity Read ↗

In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Semantic proximity Read ↗

In Vitro Activity of API-1252, a Novel FabI Inhibitor, against Clinical Isolates of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i>Semantic proximity Read ↗

In vitro activity of CEM-102 (fusidic acid) against prevalent clones and resistant phenotypes of Staphylococcus aureus.Semantic proximity Read ↗

WIN 57273, a new fluoroquinolone with enhanced in vitro activity versus gram-positive pathogens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.